Rgenta Therapeutics Inc. Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Rgenta Therapeutics is a small biotechnology company developing oral, small-molecule medicines that target RNA processing events. Its focus spans oncology and neurological disorders, aiming to address diseases driven by RNA regulation that have been difficult to treat. The company relies on a proprietary platform to identify actionable RNA processing events and to design small molecules that influence the interactions among spliceosome components, regulatory proteins, and RNAs. Headquartered in Woburn, Massachusetts, the firm is building a pipeline led by RGT-61159. In 2026, it reported positive preliminary data from ongoing Phase 1a/b trials of RGT-61159 in Adenoid Cystic Carcinoma and Colorectal Cancer, disclosed at ASCO.

Sign up for free to view info

Company overview Employee directory